Skip to main content
U.S. flag

An official website of the United States government

Developing the Therapeutic Potential of the Endocannabinoid System for Pain Treatment (R01 - Clinical Trial Optional)

Submitted by Anonymous (not verified) on

The purpose of this Funding Opportunity Announcement (FOA) is to support projects that will elucidate the therapeutic potential of the cannabinoids and endocannabinoid system in the development of mechanism-based therapies for pain.

Increasing Uptake of Evidence-Based Screening in Diverse Adult Populations (R01 Clinical Trial Optional)

Submitted by Anonymous (not verified) on

This Funding Opportunity Announcement (FOA) invites applications that seek to understand strategies to reduce disparities in the uptake of evidence-based screening (e.g. screening recommendations proven to be effective based on rigorous systematic review of scientific evidence by authoritative committees) across the adult lifespan. In this program announcement, screening is defined as a preventive service focused on detection of an undiagnosed disease in asymptomatic populations.

Engaging Men in HIV Testing, Prevention, and Care (R01 Clinical Trial Optional)

Submitted by Anonymous (not verified) on

Standard AIDS dates apply , by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates.
The first application due date for this FOA is January 7, 2019.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Molecular and Genetic Characterization of Inborn Errors of Immunity (R01 Clinical Trial Not Allowed)

Submitted by Anonymous (not verified) on

The purpose of this Funding Opportunity Announcement (FOA) is to advance the experimental validation and functional characterization of genetic variants in coding or non-coding genomic regions that result in inborn errors of immunity/primary immunodeficiency diseases and to elucidate the molecular, cellular, and immunological mechanisms of these disorders. Understanding the genetic basis of primary immunodeficiency disorders is essential for their diagnosis, prognosis, and the development of precision therapeutics.

Novel approaches to understand, prevent, treat, and diagnose coccidioidomycosis (Valley Fever) and other select endemic fungal infections (R01 Clinical Trial Not Allowed)

Submitted by Anonymous (not verified) on

The purpose of this Funding Opportunity Announcement is to support research activities that will contribute to the overall understanding of coccidioidomycosis, commonly known as Valley Fever, and other select endemic fungal diseases including histoplasmosis and blastomycosis.

Control of Sexually Transmitted Infections (STIs) Through a Comprehensive Understanding of the Natural History of Infection (R01 Clinical Trial Not Allowed)

Submitted by Anonymous (not verified) on

The purpose of this Funding Opportunity Announcement (FOA) is to encourage research to advance the understanding of natural history of infection for three sexually transmitted infections (STIs): gonorrhea, syphilis, and chlamydia. This research opportunity encourages studies that address the natural history of infection in the context of either: 1) correlates of protection, 2) host response to infection, 3) clinical endpoints of disease, or 4) biological and clinical factors that influence clearance rather than persistence of infection.

Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed)

Submitted by Anonymous (not verified) on

The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice.

Achieving Tissue Robustness Through Harnessing Immune System Plasticity (R01 Clinical Trial Not Allowed)

Submitted by Anonymous (not verified) on

This funding opportunity announcement (FOA) encourages state-of-the-art, systematic research approaches to elucidate the role of immune system plasticity in health and in the pathogenesis of dental, oral, and craniofacial (DOC) diseases. This FOA solicits applications that will seek to determine mechanisms underlying the ability or inability of the immune system to dynamically maintain its functional role against internal and external perturbations.

Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional)

Submitted by Anonymous (not verified) on

The purpose of this funding opportunity announcement (FOA) is to encourage behavioral intervention development research to test efficacy, conduct clinical trials, examine mechanisms of behavior change, determine dose-response, treatment optimization, and/or ascertain best sequencing of behavioral, combined, sequential, or integrated behavioral and pharmacological (1) drug abuse treatment interventions, including interventions for patients with comorbidities; (2) drug abuse treatment and adherence interventions; (3) drug abuse treatment and adherence interventions that utilize technologies t

Subscribe to